Skip to Content
  1. All products
  2. Recovery & Regeneration
  3. BPC-157 / TB-500
  4. Recovery & Regeneration
Pricelist: Default Pricelist Pricelist
Pricelist: Default Pricelist Pricelist
BPC-157 / TB-500

BPC-157 / TB-500

Blend · Subcutaneous, Intramuscular Refrigerate after reconstitution (2-8°C). Discard after 30 days if contamination risk or >60 days if sterile maintained. 99% Purity · USP Grade
99% Purity
PHYSICIAN USE ONLY
$ 72.00 $ 72.00

Format
⚗ blend
  • Strength
Add to cart
Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days
Clinical Description

Comprehensive recovery, accelerated tissue and tendon repair, inflammation reduction, faster healing post-injury or surgery

El Wolverine Blend combina BPC-157 y TB-500 para una recuperación integral, reparación acelerada de tejidos y tendones, reducción de la inflamación y curación más rápida después de una lesión o cirugía.

Clinical Indications
Post-procedure recovery protocolsConnective tissue and skin repair supportInflammation and healing pathway support
Recommended Stacking Protocols
✓
GHK-Cu
Collagen synthesis, skin repair
✓
Thymosin Alpha-1
Immune modulation & inflammation control
✓
CJC-1295 + Ipamorelin
GH-mediated repair & tissue growth synergy
Blend Components
Component Amount (mg)
BPC-157 5
TB-500 5

Mechanism of Action - Recovery & Tissue Repair Pathway

Targeted Signaling
Supports protocol objectives for BPC-157 / TB-500.
Clinical Modulation
Allows dose and schedule adjustments by response.
Outcome Tracking
Pairs with clinician monitoring for iterative optimization.
Starting Dose
Low initial dose
Initiation phase for tolerance and baseline response.
Titration
Escalate by protocol
Maintenance Range
Maintain physician-directed target
Adjust based on objective outcomes and physician review.
Suggested Dosing Notes

Frecuencia:1-2 veces al día (AM + PM para curación aguda; 1 vez al día para mantenimiento)

Ciclo:4-6 semanas (luego reducción gradual de mantenimiento opcional de 2 semanas)

Sitio de inyección:Rotar cerca de la lesión (subQ) o IM en grupos de músculos grandes

Period Dose Phase Clinical Notes
Weeks 1-2 Initial phase initiation Begin conservatively and monitor tolerance.
Weeks 3-6 Escalation phase escalation Increase per protocol if tolerated.
Week 7+ Maintenance phase maintenance Maintain target dose and reassess monthly.
Preparation Protocol
  1. Wolverine Blend se suministra como polvo liofilizado.
  2. Reconstituir con agua bacteriostatica.
  3. Refrigerar tras la reconstitución (2-8 °C). Desechar después de 30 días si hay riesgo de contaminación o tras 60 días si se mantiene estéril.
1
Inspect vial
Confirm vial integrity, lot, and expiration before use.
2
Aseptic reconstitution
Disinfect stopper and add bacteriostatic water slowly.
3
Gentle dissolution
Swirl gently until the solution is clear and homogeneous.
4
Prepare dose
Draw dose according to reconstitution conversion guidance.
Reconstitution & Dosing Guide
Standard 1 mL insulin syringe: 100 units = 1 mL

Total Peptide: 10 mg
BW: 2 mL
Concentration: 5mg/mL total (2.5mg/mL each peptide)
Dose Units to Draw Volume (mL) Approx. Supply
250mcg BPC + 250mcg TB 10 units - 40 doses
500mcg BPC + 500mcg TB 20 units - 20 doses
Identity
  • Product Name: BPC-157 / TB-500
  • Product Type: Blend | Subcutaneous or Intramuscular Injection
  • Strength Options: 5/5 mg, 10/10 mg
  • Available Strengths: 5mg/5mg, 10mg/10mg
  • Components: BPC-157 + TB-500
Quality & Purity
  • Purity: >= 99%
  • Sterility: Aseptic handling required
  • Purity: 99%+
Storage & Handling
  • Storage: 2-8 C refrigerated
  • Handling: Avoid heat, shaking, and direct light
  • Storage: Refrigerate after reconstitution (2-8°C). Discard after 30-60 days.

Timing: Timing-·Morning&evening dosing preferred.

Storage: Refrigerate after reconstitution (2-8°C). Discard after 30 days if contamination risk or >60 days if sterile maintained.

Frequency: Frequency:1-2xdailyforinitialhealing,then3xweeklyformaintenance. Frequency:1-2xdaily(AM +PM for acutehealing:1xdaily formaintenance). .Frequency:1-2xdaily.

Cycle: 4-6 weeks (then optional 2-week maintenance taper)

Injection Sites: Route-Subcutaneousor IntramuscularInjection